September is Sickle Cell Awareness Month, and it matters more now than at any point in the disease’s history. With FDA-approved gene therapies, new medications, and expanding newborn screening, the landscape for sickle cell disease (SCD) is shifting fast. This month is about raising awareness and advancing care—not just wearing ribbons, but understanding what 100,000 Americans and millions worldwide face every single day.
If you’re a patient, caregiver, student, or clinician, this guide covers what SCD actually is, who it affects, the treatments changing outcomes right now, and what you can do during Awareness Month to make a real difference.
What Is Sickle Cell Disease, Exactly?
Sickle cell disease is a group of inherited blood disorders caused by a mutation in the HBB gene, which codes for the beta-globin chain of hemoglobin. The result is an abnormal form of hemoglobin called hemoglobin S (HbS). When HbS loses oxygen, it polymerizes and forces red blood cells into a rigid, crescent (“sickle”) shape.
These misshapen cells don’t just carry oxygen poorly—they physically clog small blood vessels, triggering episodes of excruciating pain called vaso-occlusive crises, organ damage, stroke, and chronic anemia. Normal red blood cells live about 120 days. Sickle cells survive roughly 10–20 days, meaning the body is constantly in a state of red blood cell deficit.
Who Gets Sickle Cell Disease?
SCD is inherited in an autosomal recessive pattern—a child must receive one copy of the HbS gene from each parent. If they inherit only one copy, they have sickle cell trait (SCT), which is usually asymptomatic but means they can pass the gene to their children.
| Population | Estimated SCD Prevalence | Sickle Cell Trait Carrier Rate |
|---|---|---|
| African Americans (U.S.) | ~100,000 individuals | 1 in 13 (~8%) |
| Sub-Saharan Africa | ~5 million+ | Up to 25–30% in some regions |
| Hispanic Americans | ~1 in 16,300 births | Variable |
| Middle Eastern / Indian populations | Significant but underreported | 5–25% in endemic areas |
The sickle cell trait persists in these populations because carrying one copy of HbS confers partial protection against Plasmodium falciparum malaria—a classic example of balanced selection in human genetics.
Signs, Symptoms, and Complications
SCD isn’t one symptom—it’s a multisystem disease. Here’s what patients actually deal with:
- Pain crises (vaso-occlusive episodes): The hallmark of SCD. Can last hours to weeks, often requiring hospitalization and IV opioids.
- Chronic hemolytic anemia: Baseline hemoglobin typically runs 6–9 g/dL (normal: 12–17 g/dL).
- Acute chest syndrome: A leading cause of death in SCD—presents like pneumonia with fever, chest pain, and new infiltrates on imaging.
- Stroke: Affects ~11% of children with SCD by age 20 without preventive transfusions.
- Splenic sequestration: Especially dangerous in young children; the spleen traps sickle cells, causing rapid hemoglobin drops.
- Organ damage: Kidneys, liver, eyes, bones, and the heart all take cumulative hits over a lifetime.
- Frequent infections: Functional asplenia develops early, leaving patients vulnerable to encapsulated organisms like Streptococcus pneumoniae.
Median life expectancy for SCD patients in the U.S. has improved to roughly 54 years, up from under 20 in the 1970s. But that number still lags decades behind the general population, and quality of life remains a major challenge.
How Sickle Cell Disease Is Diagnosed
In the United States, all 50 states include SCD in newborn screening panels. The standard tests are:
- Hemoglobin electrophoresis or isoelectric focusing (IEF): Separates hemoglobin types to identify HbS, HbC, and other variants.
- High-performance liquid chromatography (HPLC): Quantifies hemoglobin fractions with high accuracy.
- Genetic (DNA) testing: Confirms the specific HBB mutation and distinguishes SCD genotypes (HbSS, HbSC, HbS-beta thalassemia, etc.).
Early diagnosis is the single biggest factor in childhood survival. Before universal screening, many children died of overwhelming sepsis or splenic sequestration before anyone knew they had SCD.
Treatments That Are Actually Changing Outcomes
Established Therapies
- Hydroxyurea: Still the backbone of SCD management. It boosts fetal hemoglobin (HbF) levels, which inhibits HbS polymerization. Studies show it reduces pain crises by ~50%, cuts hospitalizations, and lowers mortality. Recommended for all patients with HbSS starting at 9 months of age.
- L-glutamine (Endari): FDA-approved in 2017. Reduces oxidative stress in sickle red blood cells. Decreased acute pain crises by 25% in clinical trials.
- Crizanlizumab (Adakveo): A monoclonal antibody targeting P-selectin that reduces vaso-occlusive crises. Approved in 2019.
- Voxelotor (Oxbryta): Inhibits HbS polymerization directly by increasing hemoglobin’s oxygen affinity. Raises hemoglobin by ~1 g/dL on average.
- Chronic transfusion therapy: Standard for stroke prevention in children with abnormal transcranial Doppler velocities (>200 cm/s).
The Gene Therapy Revolution
In December 2023, the FDA approved two gene therapies for SCD—a genuine milestone:
- Exagamglogene autotemcel (Casgevy): The first CRISPR/Cas9-based therapy ever approved. It edits patients’ own stem cells to reactivate fetal hemoglobin production. In trials, 29 of 31 patients were free of vaso-occlusive crises for at least 12 months post-treatment.
- Lovotibeglogene autotemcel (Lyfgenia): A lentiviral gene addition therapy that introduces a modified beta-globin gene (HbAT87Q) that resists sickling.
The catch? These therapies require myeloablative chemotherapy conditioning, carry significant short-term risks, cost over $2 million per treatment, and are only available at specialized centers. Access and equity remain major concerns—especially since SCD disproportionately affects Black and underserved communities.
What You Can Do During Sickle Cell Awareness Month
Awareness without action is just a hashtag. Here are concrete steps:
- Get tested for sickle cell trait. If you don’t know your status and are from a high-risk population, ask your doctor for a hemoglobin electrophoresis.
- Donate blood. SCD patients depend on regular transfusions. Phenotypically matched donations (especially from Black donors) reduce alloimmunization.
- Advocate for funding. SCD receives roughly $1,100 in NIH funding per affected person compared to ~$8,700 for cystic fibrosis. Push for parity.
- Share patient stories. Stigma and misunderstanding—especially around pain management—remain enormous barriers to care.
- Support local SCD organizations: SCDAA (Sickle Cell Disease Association of America) and local chapters run education, screening, and patient support programs year-round.
When to See a Doctor
If you or your child has SCD, seek emergency care for:
- Fever over 101.3°F (38.5°C)—infection can become fatal within hours
- Severe pain uncontrolled by home medications
- Chest pain, difficulty breathing, or rapid heart rate (possible acute chest syndrome)
- Sudden weakness, slurred speech, or vision changes (possible stroke)
- Sudden pallor, extreme fatigue, or an enlarging spleen in a child
If you carry sickle cell trait and are planning a family, genetic counseling is strongly recommended to understand the risks for your children.
Frequently Asked Questions
Can sickle cell disease be cured?
Yes—currently through hematopoietic stem cell transplant (with a matched donor) or the newly approved gene therapies (Casgevy and Lyfgenia). Stem cell transplant from a matched sibling has a cure rate above 90% in children, but only about 18% of patients have a suitable matched donor. Gene therapy removes the donor requirement but involves intensive chemotherapy and is extremely expensive.
Is sickle cell trait the same as sickle cell disease?
No. Sickle cell trait (one copy of HbS) is generally benign. Carriers don’t experience pain crises or chronic anemia. However, trait carriers can experience complications under extreme conditions—very high altitude, severe dehydration, or intense physical exertion. Trait carriers have a 25% chance of having a child with SCD if their partner also carries the trait.
Why does sickle cell disease receive less research funding than other genetic diseases?
This is a question the SCD community has asked for decades. Despite affecting three times as many Americans as cystic fibrosis, SCD receives a fraction of the per-patient research dollars. Systemic racism, socioeconomic disparities, and lower advocacy infrastructure all play roles. Sickle Cell Awareness Month exists in part to close this gap.
What’s the life expectancy for someone with sickle cell disease today?
In the U.S., median survival is approximately 54 years, though this varies significantly by genotype and access to care. Patients with HbSS (the most severe form) tend to have shorter life expectancy than those with HbSC or HbS-beta+ thalassemia. With gene therapy becoming available, there’s real hope this number will continue to rise.
How can I support someone with sickle cell disease?
Believe their pain. SCD patients routinely face skepticism in emergency departments—studies show they wait 25–50% longer for pain medication than other patients. Offer practical help during crises, learn about the disease, and advocate for better healthcare access and insurance coverage for new treatments.
